An in vitro assay also revealed that downregulation of ORM1 led to the suppression of tumor growth and enhancement of sorafenib sensitivity without epithelial-to-mesenchymal transition alteration, which was consistent with our bioinformatic analysis. The gene discussed is ORM1; the disease is neoplasm.